At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Tranexamic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury (TAMPITI TRIAL)
In Brief
A Phase 2 clinical trial evaluating Tranexamic Acid and Placebo for Hemorrhage and 2 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effects of TXA on the immune system, its pharmacokinetics, as well as safety and efficacy in severely injured trauma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhage, Shock, Wounds and Injuries
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartFeb 2016
Primary CompletionJul 2017
Study CompletionJul 2017
TodayJul 2026
First PostedAug 31, 2015
Enrollment StartFeb 1, 2016
Primary CompletionJul 4, 2017
Study CompletionJul 7, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.8 years ago
Interventions
Tranexamic Aciddrug
Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
Placeboother
Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury